

VistaGen Therapeutics, Inc.
 Form 4
 December 26, 2013

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 SAXE JON S

(Last) (First) (Middle)

C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO, CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 VistaGen Therapeutics, Inc. [VSTA]

3. Date of Earliest Transaction
 (Month/Day/Year)
 12/20/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director
 ____ Officer (give title below)
 ____ 10% Owner
 ____ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)		
				(A) or (D)	Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities Acquired (A) or	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Underlying Security (Instr. 3 and 4)
---------------------------------	---------------------------	--------------------------------------	-----------------------------------	---------------------	--	--	---

Edgar Filing: VistaGen Therapeutics, Inc. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8) Code	Disposed of (D)		Date Exercisable	Expiration Date	Title	A
				(A)	(D)				
Stock Option (Right to Buy)	\$ 1.13	12/20/2013	D		7,500	03/24/2009	03/24/2019	Common Stock	S
Stock Option (Right to Buy)	\$ 0.5	12/20/2013	A	7,500		03/24/2009	03/24/2019	Common Stock	
Stock Option (Right to Buy)	\$ 1.5	12/20/2013	D		20,000	11/04/2011	11/04/2019	Common Stock	
Stock Option (Right to Buy)	\$ 0.5	12/20/2013	A	20,000		11/04/2011	11/04/2019	Common Stock	
Stock Option (Right to Buy)	\$ 1.5	12/20/2013	D		150,000	12/30/2011	12/30/2019	Common Stock	
Stock Option (Right to Buy)	\$ 0.5	12/20/2013	A	150,000		12/30/2011	12/30/2019	Common Stock	
Stock Option (Right to Buy)	\$ 1.75	12/20/2013	D		50,000	<u>(2)</u>	04/26/2021	Common Stock	
Stock Option (Right to Buy)	\$ 0.5	12/20/2013	A	50,000		<u>(2)</u>	04/26/2021	Common Stock	
Stock Option (Right to Buy)	\$ 2.1	12/20/2013	D		10,000	01/17/2008	01/17/2018	Common Stock	
Stock Option (Right to Buy)	\$ 0.5	12/20/2013	A	10,000		01/17/2008	01/17/2018	Common Stock	

Warrant for Common Stock	\$ 3	12/20/2013	D	50,000	02/13/2012	02/13/2016	Common Stock
Warrant for Common Stock	\$ 0.5	12/20/2013	A	50,000	02/13/2012	02/13/2016	Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SAXE JON S C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO, CA 94080				

Signatures

/s/ Jerrold D. Dotson,
Attorney-in-Fact

12/24/2013

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person agreed to cancellation of an option granted 05/11/2011 in exchange for a new option having a lower exercise price.
- (2) The option vests monthly over a period of four years commencing 4/25/2011.
- (3) The Reporting Person agreed to cancellation of a warrant issued 2/13/2012 in exchange for a new warrant having a lower exercise price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.